-
Uncategorized1 month agoOpinion: Hospitals are silencing doctors online, and it’s fueling the health misinformation crisis
I started creating health content online in medical school. I realized I could reach thousands of people in seconds and share medically accurate information with students...
-
Uncategorized1 month ago
Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand
Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand
-
Uncategorized1 month agoSTAT+: What the Trump administration wants in its next FDA leader
WASHINGTON — The Trump administration is moving quickly to identify the next commissioner of the Food and Drug Administration after the resignation of Marty Makary on...
-
Uncategorized1 month agoWhy AI Alone Isn’t Enough for Oligonucleotide Discovery
Why AI Alone Isn’t Enough for Oligonucleotide Discovery
-
Uncategorized1 month ago
Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer
Cellares, an Integrated Development and Manufacturing Organization (IDMO) that combines automated manufacturing platforms with global Smart Factory infrastructure, and ProTgen, a therapeutic company pioneering targeted Notch activators...
-
Uncategorized1 month agoU.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes
NEW YORK — About 70,000 Americans died of drug overdoses last year — about 14% fewer than the previous year, according to preliminary government data. It...
-
Uncategorized1 month agoNew InFocus eReport: Advances in cancer research
Although the cancer mortality rate has dropped by 34% since its peak in 1991, the incidence continues to increase for many common cancers. This new DDW...
-
Uncategorized1 month agoFDA’s leadership void leaves biotech with renewed ‘uncertainty’
Marty Makary’s resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.
-
Uncategorized1 month ago
Abeona pivots to T cells; AstraZeneca’s rare disease drug passes Phase 3
Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3
-
Uncategorized1 month ago
Goodbye Galapagos: chameleon company exits the island, rebrands as Lakefront
After a 12-month period that saw the Belgian biotech consider a spinout, swap out CEOs, and enter a three-way acquisition agreement involving Ouro Medicines, Galapagos now...
Hantavirus One-Shot mRNA Vaccine Fully Protects in Syrian Hamster Model
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
